Description
LHC-165 is a benzonaphthyridine TLR7 agonist.
| Product Unit Size | Cost | Quantity | Stock |
|---|
LHC-165 is a benzonaphthyridine TLR7 agonist.
| Cas No. | 1258595-14-0 |
|---|---|
| Purity | ≥99% |
| Formula | C29H32F2N3O7P |
| Formula Wt. | 603.56 |
| IUPAC Name | 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid |
| Synonym | LHC165 |
| Appearance | Pale yellow powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
Zawit M, Swami U, Awada H, et al. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med. 2021 Jun;9(12):1038. PMID: 34277838
Nucleoside (guanosine) analog; DNA chain termin...
Androgen receptor downregulator.
Nucleoside (deoxyguanosine) analog; DNA chain t...
Synthesis intermediate
ATR inhibitor.
Macrolide originally produced by Streptomyces; ...
Valsartan impurity
5-Fluorouracil prodrug, pyrimidine nucleoside a...
Isoflavone, phytoestrogen found in soy; ER agon...
Synthetic glutathione peroxidase mimetic; yeast...
Opioid neuropeptide; kyotorphin agonist.
Curcumin derivative.
β-lactam cephalosporin; penicillin binding pro...
BHA derivative.
Endogenous bombesin-related peptide, involved i...
Inhibitor of PI3K.
Histamine H2 antagonist.
Toxin produced by Canarthis vesicatoria; PP1/2A...
Endogenous peptide hormone fragment, involved i...
Steroidogenesis inhibitor